AustinPx Named Inaugural Winner of Advancing Pharmacy Research Award from The University of Texas at Austin College of Pharmacy

Fourth industry accolade in the past year recognizes breakthrough KinetiSol™ Technology for advancing pharmaceutical research and innovation

GEORGETOWN, Texas--(BUSINESS WIRE)--AustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement for orally delivered small molecule drugs, today announced it has been named the inaugural winner of the Advancing Pharmacy Research Award by The University of Texas at Austin College of Pharmacy. The award recognizes organizations and individuals who have made significant contributions to advancing pharmacy research and supporting the College’s mission.

The UT Austin College of Pharmacy, ranked No. 6 nationally by U.S. News & World Report and among the top pharmacy programs in the world, recognized AustinPx for its proprietary KinetiSol Technology, a disruptive drug delivery platform designed to overcome the solubility and formulation challenges of modern small molecule drug candidates. KinetiSol was invented by AustinPx Chief Scientific Officer Dave Miller and Chief Technology Officer Chris Brough, who are both former graduate students at the College of Pharmacy.

“As an Austin-based organization with deep ties to UT, we are honored to be recognized by the College of Pharmacy with this award, a testament to both AustinPx and UT’s impact on a local and global level,” said Elizabeth Hickman, Chief Executive Officer of AustinPx. “Already adopted by most large pharmaceutical companies, we believe adoption of KinetiSol will only accelerate as our industry continues to confront molecules once considered undevelopable.”

KinetiSol is a solvent-free, fusion-based process that generates high-performance amorphous solid dispersions (ASD) in under 20 seconds. Its streamlined design and small operational footprint lead to faster development and a more cost-effective, scalable, and environmentally friendly ASD manufacturing process. Due to its broad formulation design space, KinetiSol supports thermally sensitive and poor solvent-soluble APIs, enabling compounds out of reach for existing technologies. Beyond solubility enhancement, KinetiSol ASDs demonstrate improved flowability, compressibility, and ASD loading.

This recognition follows a series of industry honors for KinetiSol, including the Accelerating Innovation Award at the 2024 CPHI Pharma Awards and Best Technologies Innovation at Interphex 2024. KinetiSol was also recently named as a finalist for the Sustainability Award at the 2025 CPHI Pharma Awards, where winners will be announced in late October. Together, these accolades highlight growing industry adoption of KinetiSol as a breakthrough solution for complex molecules and challenging drug delivery needs.

All 2025 College of Pharmacy Award recipients will be recognized on Friday, October 24, at the Dose of Distinction celebration dinner in Austin. For more information about KinetiSol and AustinPx’s industry-leading solutions, visit www.austinpx.com/kinetisol/

About AustinPx

AustinPx, Pharmaceutics and Manufacturing, is a contract development and manufacturing organization (CDMO) providing analytical and formulation development services and cGMP manufacturing for small molecule drugs. AustinPx specializes in phase-appropriate development strategies, speed to clinic and market strategies, and bioavailability enhancement of poorly soluble molecules - including our next generation amorphous dispersion platform, KinetiSol™ Technology.

Media Contact
Julian Byrne
anthonyBarnum Public Relations
julian.byrne@anthonybarnum.com
+1 (512) 665-9258